I use yahoo in getting a very rough idea for investment purposes (knowing that it is not very accurate) I look at SEC filings... so by my logic it is safe to say I don't have investment interest in LJPC at this time :).
BMRN had previously said they prefer not to buy a company unless it was the only way to do the deal.
I was basically saying what you said in your first point though not as succinctly :).
I am guessing a buyout would have be in the 300% range which makes it about 150 million today. I don't have a problem with what biomarin did and like the lower risk approach.
BioMarin-BMRN licensing deal with La Jolla makes sense, says Citigroup Citigroup believes BioMarin's in-licensing of Riquent from La Jolla Pharmaceutical (LJPC) makes sense as the company put only $52.5M at risk for the option of participation of in a Phase III program for a sizable indication with high unmet medical need. Citigroup maintains a Buy rating on BMRN shares.
Market Data 
Markets 
AI
